Low-doses aspirin in the primary prevention of cardiovascular disease in patients with diabetes: Meta-analysis stratified by baseline cardiovascular risk.
Fiche publication
Date publication
janvier 2022
Journal
Diabetes & metabolic syndrome
Auteurs
Membres identifiés du Cancéropôle Est :
Pr VERGES Bruno
Tous les auteurs :
Masson W, Barbagelata L, Lavalle-Cobo A, Lobo M, Masson G, Nogueira JP, Vergès B
Lien Pubmed
Résumé
The aim of this meta-analysis was to analyze the risks and benefits of low-dose aspirin in patients with T2D without cardiovascular conditions according to the baseline cardiovascular risk.
Mots clés
Aspirin, Cardiovascular risk, Major cardiovascular events, Type 2 diabetes
Référence
Diabetes Metab Syndr. 2022 Jan 8;16(1):102391